C
Chitra Hosing
Researcher at University of Texas MD Anderson Cancer Center
Publications - 506
Citations - 16609
Chitra Hosing is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 59, co-authored 463 publications receiving 13941 citations. Previous affiliations of Chitra Hosing include University of Texas at Austin & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu,David Marin,Pinaki P. Banerjee,Homer A. Macapinlac,Philip A. Thompson,Rafet Basar,Lucila Nassif Kerbauy,Bethany J Overman,Peter F. Thall,Mecit Kaplan,Vandana Nandivada,Indresh Kaur,Ana Karen Nunez Cortes,Kai Cao,May Daher,Chitra Hosing,Evan N. Cohen,Partow Kebriaei,Rohtesh S. Mehta,Sattva S. Neelapu,Yago Nieto,Michael Wang,William G. Wierda,Michael J. Keating,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani +26 more
TL;DR: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects.
Journal ArticleDOI
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
John F. DiPersio,Edward A. Stadtmauer,Auayporn Nademanee,Ivana N. Micallef,Patrick J. Stiff,Jonathan L. Kaufman,Richard T. Maziarz,Chitra Hosing,Stefan Fruehauf,Mitchell E. Horwitz,Dennis L. Cooper,Gary Bridger,Gary Calandra +12 more
TL;DR: Plerixafor and G- CSF were well tolerated, and significantly more patients collected the optimal CD34(+) cell/kg target for transplantation earlier compared with G-CSF alone.
Journal ArticleDOI
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke,Sattva S. Neelapu,Nancy L. Bartlett,Tanya Siddiqi,Julio C. Chavez,Chitra Hosing,Armin Ghobadi,Lihua E. Budde,Adrian Bot,John M. Rossi,Yizhou Jiang,Allen Xue,Meg Elias,Jeff Aycock,Jeff Wiezorek,William Y. Go +15 more
TL;DR: This regimen of KTE-C19 was safe for further study in phase 2 and induced durable remissions in patients with refractory DLBCL and demonstrated peak expansion within 2 weeks and continued to be detectable at 12+ months in patientswith ongoing CR.
Journal ArticleDOI
Cord-blood engraftment with ex vivo mesenchymal-cell coculture.
Marcos de Lima,Ian McNiece,Simon N. Robinson,Mark F. Munsell,Mary Eapen,Mary M. Horowitz,Amin M. Alousi,Rima M. Saliba,John McMannis,Indreshpal Kaur,Partow Kebriaei,Simrit Parmar,Uday R. Popat,Chitra Hosing,Richard E. Champlin,Catherine M. Bollard,Jeffrey J. Molldrem,Roy B. Jones,Yago Nieto,Borje S. Andersson,Nina Shah,Betul Oran,Laurence J.N. Cooper,Laura L. Worth,Muzaffar H. Qazilbash,Martin Korbling,Gabriela Rondon,Stefan O. Ciurea,Doyle Bosque,I. Maewal,Paul J. Simmons,Elizabeth J. Shpall +31 more
TL;DR: Transplantation of cord-blood cells expanded ex vivo in cocultures with allogeneic mesenchymal stromal cells appeared to be safe and effective and significantly improved engraftment, as compared with unmanipulated cord blood only.
Journal ArticleDOI
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Conrad Russell Y. Cruz,Kenneth P. Micklethwaite,Barbara Savoldo,Carlos A. Ramos,Sharon Lam,Stephanie Ku,Oumar Diouf,Enli Liu,A. John Barrett,Sawa Ito,Elizabeth J. Shpall,Robert A. Krance,Robert A. Krance,Rammurti T. Kamble,Rammurti T. Kamble,George Carrum,George Carrum,Chitra Hosing,Adrian P. Gee,Zhuyong Mei,Bambi Grilley,Helen E. Heslop,Helen E. Heslop,Cliona M. Rooney,Malcolm K. Brenner,Malcolm K. Brenner,Catherine M. Bollard,Catherine M. Bollard,Gianpietro Dotti +28 more
TL;DR: CD19.CAR-VSTs display antitumor activity and, because their number may be increased in the presence of viral stimuli, earlier treatment post-HSCT (when lymphodepletion is greater and the incidence of viral infection is higher) or planned vaccination with viral antigens may enhance disease control.